Physician profile
Jack D Fair
NPI 1568673028
$7,435.40
in general payments reported to CMS, 2019-2025
39 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $1,008 · 2021: $1,034 · 2022: $887 · 2023: $1,282 · 2024: $1,224 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,722.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,314.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,061.55 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $729.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $669.13 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $636.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $445.33 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $260.31 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $212.78 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Kowa Pharmaceuticals America, INC. | $201.74 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Astellas Pharma US INC | $166.78 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.98 | 2020-2025 | Ofev, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $134.44 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.04 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $122.22 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $113.33 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Fair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.